Delcath Systems (DCTH)

• Market cap: $396M
• 1 day: -2.78%
• 5 days: -12.07%
• 1 month: -27.09%
• 3 months: -1.98%
• 6 months: 24.42%
• Year to date: -5.87%
• 1 year: 209.92%
• 5 years: 54.96%
• 10 years: -100.00%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Employees: 76

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

275% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 8

178% more call options, than puts

Call options by funds: $2.03M | Put options by funds: $730K

154% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 13

81% more capital invested

Capital invested by funds: $90.9M [Q3] → $165M (+$73.8M) [Q4]

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

30% more funds holding

Funds holding: 69 [Q3] → 90 (+21) [Q4]

5.64% more ownership

Funds ownership: 37.16% [Q3] → 42.8% (+5.64%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 77% upside
• Avg. target: $23 90% upside
• High target: $24 102% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 45 / 199 met price target	102% upside $24	Buy Maintained	7 Mar 2025
Craig-Hallum Chase Knickerbocker 41% 1-year accuracy 11 / 27 met price target	77% upside $21	Buy Maintained	17 Jan 2025